摘要
目的检测癌-睾丸抗原(cancer-testis antigen,CTA)MAGE-A1(黑色素瘤抗原A1)在鼻咽癌(nasopharyngeal cancer,NPC)和非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中的表达,为以MAGE-A1蛋白为基础制备特异性肿瘤疫苗,拓宽NPC及NSCLC诊断标记物及其治疗NPC及NSCLC提供依据。方法用免疫组织化学技术检测病理确诊的50例NPC和43例NSCLC组织及其非癌组织(鼻炎,鼻息肉,肺炎,肺结核等非癌疾病组织)中MAGE-A1的表达情况,并将其表达结果与临床指标进行统计学分析。结果 MAGE-A1在NPC中的阳性表达率为42.00%(21/50),在NSCLC中的阳性表达率为72.09%(31/43),在非癌性的10例鼻咽组织及6例肺组织中均为阴性表达。MAGE-A1的表达与NPC患者的性别、年龄、疾病的临床分期、有无淋巴结转移无明显相关性(P>0.05);与NSCLC患者的性别、年龄、疾病的临床分期、肿瘤的大小、病理类型、有无淋巴结转移亦无明显相关性(P>0.05)。结论 MAGE-A1有望作为靶抗原用于NPC及NSCLC的免疫诊断和免疫治疗。
This study is to investigate the expression of cancer testis antigen （CTA） MAGE-A1 in human nasopharyngeal cancer （NPC） and non-small cell lung cancer （NSCLC） and provide data for developing special vaccine,immunodiagnosis,and immunotherapy of NPC and NSCLC PV9000 immunohistochemistry method was used to detect the expression of MAGE-A1 antigen in tissues of 50 NPC patients and 43 NSCLC patients as well as non-cancer patients （rhinitis,rhinopolyp,pneumonia,and pulmonary tuberculosis,et al）.The results of expression and clinical parameters were analyzed with SPSS 13.0 statistic analysis software.Expression of MAGEA1 was observed in 21 out of 50 NPC cases and 31 out of 43 NSCLC cases;the expression of MAGE-A1 in NPC and NSCLC was not correlated with gender,age,lymph node metastasis status,or TNM stages.We speculate that MAGE-A1 antigen can be used as a target antigen for immunodiagnosis and immunotherapy of NPC and NSCLC.
出处
《免疫学杂志》
CAS
CSCD
北大核心
2010年第8期706-709,共4页
Immunological Journal
基金
广西科技厅基金(桂科基0575059)
